


**Ce document liste les publications des travaux
des équipes de recherche du Cancéropôle Grand Ouest,
sorties de septembre à octobre 2020, classées par réseaux du CGO.**

**Pour accéder plus rapidement aux publications des réseaux qui vous intéressent,
vous pouvez cliquer directement sur les logos ci-dessous :**



Et pour les publications inter-réseaux :



Réseau « Vectorisation, Imagerie, Radiothérapies »

[Nanomedicine to target multidrug resistant tumors.](#)

Lepeltier E, Rijo P, Rizzolio F, Popovtzer R, Petrikaite V, Assaraf YG, Passirani C.
Drug Resist Updat. 2020 Sep;52:100704.

[RNA-sequencing of IDH-wild-type glioblastoma with chromothripsis identifies novel gene fusions with potential oncogenic properties.](#)

Ah-Pine F, Casas D, Menei P, Boisselier B, Garcion E, Rousseau A.
Transl Oncol. 2020 Oct 15;14(1):100884.

[Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.](#)

Amrane K, le Pennec R, Schick U, Metges JP, Abgral R.
Clin Nucl Med. 2020 Sep;45(9):707-708.

[The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma.](#)

Girard A, Vila Reyes H, Shaish H, Grellier JF, Dercle L, Salaün PY, Delcroix O, Rouanne M.
Front Oncol. 2020 Oct 6;10:565086.

[Radiotherapy target volume definition in newly diagnosed high grade glioma using 18F-FET PET imaging and multiparametric perfusion MRI: A prospective study \(IMAGG\).](#)

Dissaux G, Dissaux B, Kabbaj OE, Gujral DM, Pradier O, Salaün PY, Seizeur R, Bourhis D, Ben Salem D, Querellou S, Schick U.
Radiother Oncol. 2020 Sep;150:164-171.

[Use of radiomics in the radiation oncology setting: Where do we stand and what do we need?](#)

Schick U, Lucia F, Bourbonne V, Dissaux G, Pradier O, Jaouen V, Tixier F, Visvikis D, Hatt M.
Cancer Radiother. 2020 Oct;24(6-7):755-761.

[French Health Authority certification visit in a radiotherapy department.](#)

Ponsard N, Heddadi L, Pradier O.
Cancer Radiother. 2020 Oct;24(6-7):722-725.

[Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.](#)

Guénolé M, Lucia F, Bourbonne V, Dissaux G, Reygagne E, Goasduff G, Pradier O, Schick U.
BMC Cancer. 2020 Oct 13;20(1):991.

[Radiation-oncology horizon 2030: From microbiota to plasma laser.](#)

Beudelot C, Bayart E, Thariat J, Bourcier C, Denis F, Hatt M, Pasquier D, Verry C, Deutsch É, Levy A.
Cancer Radiother. 2020 Oct;24(6-7):744-750.

[Non-invasive imaging prediction of tumor hypoxia: a novel developed and externally validated CT and FDG-PET-based radiomic signatures.](#)

Sanduleanu S, Jochems A, Upadhaya T T, Even AJG, Leijenaar RTH, Dankers FJWM, Klaassen R, Woodruff HC, Hatt M, Kaanders HJAM, Hamming-Vrieeze O, van Laarhoven H HWM, Subramiam R RM, H Huang S S, O'Sullivan B, Bratman SV, Dubois LJ, Miclea RL, Di Perri D, Geets X, Crispin-Ortuzar M, Apte A, Deasy JO, Hun Oh J, Lee NY, Humm JL, Schöder H, De Ruysscher D, Hoebbers F, Lambin P.
Radiother Oncol. 2020 Oct 30:S0167-8140(20)30852-5.

[Surface imaging for real-time patient respiratory function assessment in intensive care.](#)

Nazir S, Pateau V, Bert J, Clement JF, Fayad H, l'Her E, Visvikis D.
Med Phys. 2020 Oct 28.

[Enabling Indium Channels for Mass Cytometry by Using Reinforced Cyclam-Based Chelating Polylysine.](#)

Grenier L, Beyler M, Closson T, Zabinyakov N, Bouzekri A, Zhang Y, Pichaandi JM, Winnik MA, Liu P, Ornatsky OI, Baranov V, Tripier R.
Bioconjug Chem. 2020 Sep 16;31(9):2103-2115.

[Reply to the 'Comment on "Investigation of Zr\(IV\) and ⁸⁹Zr\(IV\) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging"' by A. Bianchi and M. Savastano, Chem. Commun., 2020, 56, DOCC01189D.](#)

Guérard F, Lee YS, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW
Chem Commun (Camb). 2020 Oct 25;56(83):12667-12668.

[⁶⁸Ga-Labelled Carbon Nanoparticles for Ventilation PET/CT Imaging: Physical Properties Study and Comparison with Technegas®.](#)

Blanc-Béguin F, Eliès P, Robin P, Tripier R, Kervarec N, Lemarié CA, Hennebicq S, Tromeur C, Cogulet V, Salaün PY, Le Roux PY.
Mol Imaging Biol. 2020 Sep 4.

[Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease.](#)

Gouard S, Maurel C, Marionneau-Lambot S, Dansette D, Bailly C, Guérard F, Chouin N, Haddad F, Alliot C, Gaschet J, Eychenne R, Kraeber-Bodéré F, Chérel M.
Cancers (Basel). 2020 Sep 22;12(9):2721.

[Questioning the Affinity of Electrophilic Astatine for Sulfur-containing Compounds: Unexpected Bindings Revealed.](#)

Bassal F, Champion J, Pardoue S, Seydou M, Sabatié-Gogova A, Deniaud D, Questel JL, Montavon G, Galland N.
Inorg Chem. 2020 Oct 5;59(19):13923-13932.

[Long-term Trace of Radiation Pneumonitis With ¹⁸F-Fluoroestradiol.](#)

Morel A, Maucherat B, Chiavassa S, Kraeber-Bodéré F, Rousseau C.
Clin Nucl Med. 2020 Sep;45(9):e403-e405.

[From a PMT-based to a SiPM-based PET system: a study to define matched acquisition/reconstruction parameters and NEMA performance of the Biograph Vision 450.](#)

Carlier T, Ferrer L, Conti M, Bodet-Milin C, Rousseau C, Bercier Y, Bendriem B, Kraeber-Bodéré F.
EJNMMI Phys. 2020 Sep 3;7(1):55.

[Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.](#)

Blanc-Durand P, Jégou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodéré F, Carlier T, Le Gouill S, Casasnovas RO, Meignan M, Itti E.
Eur J Nucl Med Mol Imaging. 2020 Oct 24.

[Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials.](#)

Michaud-Robert AV, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, Moreau P, Kraeber-Bodere F, Nanni C, Bodet-Milin C.

Cancers (Basel). 2020 Sep 6;12(9):2532.

[Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.](#)

Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, Moreau P, Touzeau C, Zamagni E, Bodet-Milin C, Kraeber-Bodéré F, Mateus D, Carlier T

Eur J Nucl Med Mol Imaging. 2020 Oct 2.

[Treatment of radiation-induced late effects: What's new?.](#)

Chargari C, Supiot S, Hennequin C, Chapel A, Simon JM.

Cancer Radiother. 2020 Oct;24(6-7):602-611.

[Do dose constraints to organs at risk need to be adapted when irradiation is combined with drug therapy?.](#)

Jouglar E, Doyen J, Supiot S.

Cancer Radiother. 2020 Oct;24(6-7):594-601.

[Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy](#)

Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N.

Molecules. 2020 Sep 2;25(17):4012.

[Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms.](#)

Bertin H, Gomez-Brouchet A, Rédini F.

Crit Rev Oncol Hematol. 2020 Oct 10;156:103126.

[PTPN11 mutations in canine and human disseminated histiocytic sarcoma.](#)

Hédan B, Rault M, Abadie J, Ulvé R, Botherel N, Devauchelle P, Copie-Bergman C, Cadieu E, Parrens M, Alten J, Zalcman EL, Cario G, Damaj G, Mokhtari K, Le Loarer F, Coulomb-Lhermine A, Derrien T, Hitte C, Bachelot L, Breen M, Gilot D, Blay JY, Donadieu J, André C.

Int J Cancer. 2020 Sep 15;147(6):1657-1665.

[Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study.](#)

Hermann AL, Dieudonné A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group.

Radiology. 2020 Sep;296(3):673-684.

[Planning With Patient-Specific Rectal Sub-Region Constraints Decreases Probability of Toxicity in Prostate Cancer Radiotherapy.](#)

Lafond C, Barateau A, N'Guessan J, Perichon N, Delaby N, Simon A, Haigron P, Mylona E, Acosta O, de Crevoisier R

Front Oncol. 2020 Sep 11;10:1597.

[PET and MRI guided adaptive radiotherapy: Rational, feasibility and benefit.](#)

Thureau S, Briens A, Decazes P, Castelli J, Barateau A, Garcia R, Thariat J, de Crevoisier R.

Cancer Radiother. 2020 Oct;24(6-7):635-644.

[Antibody-Drug Conjugates: The Last Decade.](#)

Joubert N, Beck A, Dumontet C, Denevault-Sabourin C.
Pharmaceuticals (Basel). 2020 Sep 14;13(9):245.



Réseau « Cancers des Tissus Hormono-dépendants »

[Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications.](#)

Diamand R, Ploussard G, Roumiguié M, Malavaud B, Oderda M, Gontero P, Fourcade A, Fournier G, Benamran D, Iselin C, Fiard G, Descotes JL, Peltier A, Simone G, Roche JB, Roumeguère T, Albisinni S.
Urol Oncol. 2020 Oct 8:S1078-1439(20)30399-9.

[A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry.](#)

Darst BF, Wan P, Sheng X, Bensen JT, Ingles SA, Rybicki BA, Nemesure B, John EM, Fowke JH, Stevens VL, Berndt SI, Huff CD, Strom SS, Park JY, Zheng W, Ostrander EA, Walsh PC, Srivastava S, Carpten J, Sellers TA, Yamoah K, Murphy AB, Sanderson M, Crawford DC, Gapstur SM, Bush WS, Aldrich MC, Cussenot O, Yeager M, Petrovics G, Cullen J, Neslund-Dudas C, Kittles RA, Xu J, Stern MC, Kote-Jarai Z, Govindasami K, Chokkalingam AP, Multigner L, Parent ME, Menegaux F, Cancel-Tassin G, Kibel AS, Klein EA, Goodman PJ, Drake BF, Hu JJ, Clark PE, Blanchet P, Casey G, Hennis AJM, Lubwama A, Thompson IM Jr, Leach R, Gundell SM, Pooler L, Xia L, Mohler JL, Fontham ETH, Smith GJ, Taylor JA, Eeles RA, Brureau L, Chanock SJ, Watya S, Stanford JL, Mandal D, Isaacs WB, Cooney K, Blot WJ, Conti DV, Haiman CA
Eur Urol. 2020 Sep;78(3):316-320.

[African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer.](#)

Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K; UKGPCS Collaborators, Lophatananon A, Tangen CM, Goodman PJ, Thompson IM Jr, Blot WJ, Zheng W, Kibel AS, Drake BF, Cussenot O, Cancel-Tassin G, Menegaux F, Truong T, Park JY, Lin HY, Bensen JT, Fontham ETH, Mohler JL, Taylor JA, Multigner L, Blanchet P, Brureau L, Romana M, Leach RJ, John EM, Fowke J, Bush WS, Aldrich M, Crawford DC, Srivastava S, Cullen JC, Petrovics G, Parent M^É, Hu JJ, Sanderson M, Mills IG, Andreassen OA, Dale AM, Seibert TM; PRACTICAL Consortium.
Int J Cancer. 2020 Sep 15.

[Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.](#)

Marra G, Valerio M, Heidegger I, Tsaour I, Mathieu R, Ceci F, Ploussard G, van den Bergh RCN, Kretschmer A, Thibault C, Ost P, Tilki D, Kasivisvanathan V, Moschini M, Sanchez-Salas R, Gontero P, Karnes RJ, Montorsi F, Gandaglia G; EAU-YAU Prostate Cancer Working Party.
Eur Urol Oncol. 2020 Oct;3(5):565-581.

[Radical prostatectomy for prostate cancer, perioperative management by French urologists in 2018](#)

Gas J, Dominique I, Mathieu R, Poinas G, Cuvelier G, Rebillard X, Corbel L; Commission Ambu-RAAC du CPP-AFU.
Prog Urol. 2020 Sep;30(10):541-546.

[Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide: a direct comparison based on a 2014-2018 French population study \(the SPEAR cohort\).](#)

Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E.
Am J Epidemiol. 2020 Sep 18:kwaa190.

[Neurofibromin Structure, Functions and Regulation.](#)

Bergoug M, Doudeau M, Godin F, Mosrin C, Vallée B, Bénédetti H.
Cells. 2020 Oct 27;9(11):E2365.

[Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.](#)

Chelly S, Maulaz P, Bigot P, Azzouzi AR, Lebdaï S.
Asian J Androl. 2020 Sep-Oct;22(5):454-458.

[Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort.](#)

Percot M, Robert G, Bladou F, Ferrière JM, Bensadoun H, Bernhard JC, Alezra E, Capon G, Sénéchal C, Gourtaud G, Brureau L, Roux V, Blanchet P, Eyraud R.
Prog Urol. 2020 Sep;30(10):532-540.

Réseau « Immunothérapies »

[Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.](#)

Luque Paz D, Jouanneau-Courville R, Riou J, Ianotto JC, Boyer F, Chauveau A, Renard M, Chomel JC, Cayssials E, Gallego-Hernanz MP, Pastoret C, Murati A, Courtier F, Rousselet MC, Quintin-Roué I, Cottin L, Orvain C, Thépot S, Chrétien JM, Delneste Y, Ifrah N, Blanchet O, Hunault-Berger M, Lippert E, Ugo V.
Blood Adv. 2020 Oct 13;4(19):4887-4897

[Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?](#)

Camuset M, Huault A, Grain A, Clémenceau B, Rialland F, Thomas C, Chevallier P, Béné MC, Eveillard M.
Hematol Oncol. 2020 Sep 7.

[\$\gamma 9\delta 2\$ cell diversity and the receptor interface with tumor cells.](#)

Vyborova A, Beringer DX, Fasci D, Karaiskaki F, van Diest E, Kramer L, de Haas A, Sanders J, Janssen A, Straetemans T, Olive D, Leusen J, Boutin L, Nedellec S, Schwartz SL, Wester MJ, Lidke KA, Scotet E, Lidke DS, Heck AJ, Sebestyen Z, Kuball J.
J Clin Invest. 2020 Sep 1;130(9):4637-4651.

[Beyond CAR T cells: Engineered \$\gamma 9\delta 2\$ T cells to fight solid tumors.](#)

Rafia C, Harly C, Scotet E.
Immunol Rev. 2020 Sep 23.

[Contribution of the SYK Tyrosine kinase expression to human iNKT self-reactivity.](#)

Perroteau J, Navet B, Devilder MC, Hesnard L, Scotet E, Gapin L, Saulquin X, Gautreau-Rolland L.
Eur J Immunol. 2020 Oct;50(10):1454-1467.

[Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.](#)

Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguïn N, Deschamps L, Grob JJ, Dréno B, Scheer-Senarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guégan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Lévy V; Groupe de Cancérologie Cutanée30.
J Clin Oncol. 2020 Sep 10;38(26):3051-3061.



[Panniculitis during BRAF inhibitor and/or MEK inhibitor therapy: A new case report and literature review.](#)

Piroth M, Frénard C, Eugène-Lamer J, Dreno B, Quéreux G
Ann Dermatol Venereol. 2020 Sep 15:S0151-9638(20)30317-3.

[Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma.](#)

Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M.
Clin Lymphoma Myeloma Leuk. 2020 Sep 18:S2152-2650(20)30511-5.

[The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force.](#)

Garbe C, Peris K, Soura E, Forsea AM, Hauschild A, Arenbergerova M, Bylaite M, Del Marmol V, Bataille V, Samimi M, Gandini S, Saiag P, Eigentler TK, Lallas A, Zalaudek I, Lebbe C, Grob JJ, Hoeller C, Robert C, Dréno B, Arenberger P, Kandolf-Sekulovic L, Kaufmann R, Malvey J, Puig S, Leiter U, Ribero S, Papadavid E, Quaglino P, Bagot M, John SM, Richard MA, Trakatelli M, Salavastru C, Borradori L, Marinovic B, Enk A, Pincelli C, Ioannides D, Paul C, Stratigos AJ.
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2183-2197.

[Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: lessons from a prospective multicentric study.](#)

Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P. Br
J Clin Pharmacol. 2020 Oct 28.

[4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis.](#)

Granel J, Lemoine R, Morello E, Gallais Y, Mariot J, Drapeau M, Musnier A, Poupon A, Pugnière M, Seren S, Nouar D, Gouilleux-Gruart V, Watier H, Korkmaz B, Hoarau C.
Front Immunol. 2020 Sep 25;11:573040

[Molecular description of ANGPT2 associated colorectal carcinoma.](#)

Jary M, Hasanova R, Vienot A, Asgarov K, Loyon R, Tirole C, Bouard A, Orillard E, Klajer E, Kim S, Viot J, Colle E, Adotevi O, Bouché O, Lecomte T, Borg C, Feugeas JP.
Int J Cancer. 2020 Oct 1;147(7):2007-2018.

[Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.](#)

Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, Pautier P, Angeles MA, Delanoy N, Lefeuvre-Plesse C, Cancel M, Treilleux I, Augereau P, Lavoue V, Kalbacher E, Berton Rigaud D, Selle F, Nadeau C, Gantzer J, Joly F, Guillemet C, Pomel C, Favier L, Abdeddaim C, Venat-Bouvet L, Provansal M, Fabbro M, Kaminsky MC, Lortholary A, Lecuru F, Coquard IR, de La Motte Rouge T.
Gynecol Oncol. 2020 Sep;158(3):666-672.

[Fluorescent peptide biosensor for probing CDK6 activity in lung cancer cell extracts.](#)

Soamalala J, Diot S, Pellerano M, Blanquart C, Galibert M, Jullian M, Puget K, Morris MC.
Chembiochem. 2020 Oct 28.



Réseau « Niches et Epigénétique des Tumeurs »

[Reactive oxygen species levels differentiate CD34+ human progenitors based on CD38 expression.](#)

Vignon C, Lachot S, Foucault A, Ravalet N, Gyan E, Picou F, Herault B, Le Nail LR, Bene MC, Herault O. Cytometry B Clin Cytom. 2020 Sep 4.

[Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature.](#)

Nehme A, Dakik H, Picou F, Cheok M, Preudhomme C, Dombret H, Lambert J, Gyan E, Pigneux A, Récher C, Béné MC, Gouilleux F, Zibara K, Herault O, Mazurier F. Blood Adv. 2020 Oct 27;4(20):5322-5335.

[Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.](#)

Nehme R, Hallal R, El Dor M, Kobeissy F, Gouilleux F, Mazurier F, Zibara K. Curr Med Chem. 2020 Sep 8.

[Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells.](#)

Hergesheimer R, Lanznaster D, Bourgeais J, Héroult O, Vourc'h P, Andres CR, Corcia P, Blasco H. Cells. 2020 Sep 29;9(10):2198.

[ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance.](#)

Caillot M, Zylbersztejn F, Maitre E, Bourgeais J, Héroult O, Sola B. Cells. 2020 Oct 26;9(11):E2357.

[Retrospective review of end-of-life care in the last month of life in older patients with multiple myeloma: what collaboration between haematologists and palliative care teams?](#)

Chalopin T, Vallet N, Benboubker L, Ochmann M, Gyan E, Chaumier F. BMJ Support Palliat Care. 2020 Sep 4;bmjspcare-2020-002293.

[The emerging potential of cold atmospheric plasma in skin biology.](#)

Busco G, Robert E, Chettouh-Hammas N, Pouvesle JM, Grillon C. Free Radic Biol Med. 2020 Oct 8;161:290-304.

[Stromal cells regulate malignant B-cell spatial organization, survival, and drug response in a new 3D model mimicking lymphoma tumor niche](#)

Lamaison C, Latour S, Hélaine N, Le Morvan V, Monvoisin C, Mahouche I, Dussert C, Dessauge E, Pangault C, Seffals M, Broca-Brisson L, Alessandri K, Soubeyran P, Mourcin F, Nassoy P, Recher G, Tarte K, Bresson-Bepoldin L
BioRxiv Posted October 17, 2020.

[Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse.](#)

Pangault C, Amé-Thomas P, Rossille D, Dulong J, Caron G, Nonn C, Chatonnet F, Desmots F, Launay V, Lamy T, Fest T, Tarte K. Cancers (Basel). 2020 Oct 5;12(10):2865.

[Human Lymphoid Stromal Cells Contribute to Polarization of Follicular T Cells Into IL-4 Secreting Cells.](#)

Misiak J, Jean R, Rodriguez S, Deleurme L, Lamy T, Tarte K, Amé-Thomas P. Front Immunol. 2020 Oct 2;11:559866.

[Three-Dimensional Culture Systems in Gastric Cancer Research.](#)

Alzeeb G, Metges JP, Corcos L, Le Jossic-Corcos C.
Cancers (Basel). 2020 Sep 29;12(10):2800.

[Prognostic impact of cancer stem cell markers ABCB1, NEO1 and HIST1H2AE in colorectal cancer.](#)

Badic B, Durand S, El Khoury F, De La Grange P, Gentien D, Simon B, Le Jossic-Corcos C, Corcos L.
Am J Transl Res. 2020 Sep 15;12(9):5797-5807.

[Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.](#)

Le Bris Y, Magrangeas F, Moreau A, Chiron D, Guérin-Charbonnel C, Theisen O, Pichon O, Canioni D, Burrioni B, Maisonneuve H, Thieblemont C, Oberic L, Gyan E, Pellat-Deceunynck C, Hermine O, Delfau-Larue MH, Tessoulin B, Béné MC, Minvielle S, Le Gouill S.
Hematol Oncol. 2020 Oct;38(4):446-455.

[Vesiclemia: counting on extracellular vesicles for glioblastoma patients.](#)

Sabbagh Q, Andre-Gregoire G, Guevel L, Gavard J.
Oncogene. 2020 Sep;39(38):6043-6052.

[Lysosomes in glioblastoma: pump up the volume.](#)

Jacobs KA, Maghe C, Gavard J.
Cell Cycle. 2020 Sep;19(17):2094-2104.

[From 1957 to Nowadays: A Brief History of Epigenetics.](#)

Peixoto, P., Cartron, P. F., Serandour, A. A., & Hervouet, E. 2020 Oct 14;21(20):7571.

[Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo.](#)

PJ, Pineau R, Voutetakis K, Samal J, Jégou G, Lhomond S, Gorman AM, Samali A, Patterson JB, Zeng Q, Pandit A, Aubry M, Soriano N, Etcheverry A, Chatziioannou A, Mosser J, Avril T, Chevet E
Cancer Lett. 2020 Sep 1;494:73-83.

[Mitochondria transfer from tumor-activated stromal cells \(TASC\) to primary Glioblastoma cells.](#)

Salaud C, Alvarez-Arenas A, Geraldo F, Belmonte-Beitia J, Calvo GF, Gratas C, Pecqueur C, Garnier D, Pérez-García V, Vallette FM, Oliver L.
Biochem Biophys Res Commun. 2020 Sep 14:S0006-291X(20)31699-5.

Réseau « Molécules Marines, Métabolisme et Cancer »

[Abemaciclib, A Recent Novel FDA-Approved Small Molecule Inhibiting Cyclin-Dependant Kinase 4/6 for the Treatment of Metastatic Breast Cancer: A mini-review.](#)

Voli LA, Mamyrbékova JA, Bazureau JP.
Open J. Med. Chem. 2020, 10, 128-138. **CGO remercié**

[Synthesis of new 2-\(phenylamino\)-4H-chromene-3-carbonitrile derivatives and their effects on tumor cell Lines and against protein kinases.](#)

Bouattour A, Fakhfakh M, Abid S, Paquin L, Le Guével R, Corlu A, Ruchaud S, Bach S, Bazureau JP, Ammar H.
Internat. J.Org. Chem. 2020, 10, 88-103. **CGO remercié**



[Discovery of simplified benzazole fragments derived from the marine benzoscaptopin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1.](#)

Benchekroun M, Ermolenko L, Tran MQ, Vagneux A, Nedev H, Delehouzé C, Souab M, Baratte B, Josselin B, Iorga BI, Ruchaud S, Bach S, Al-Mourabit A.

Eur J Med Chem. 2020 Sep 1;201:112337. **CGO remercié**

[Interaction between adipose tissue and cancer cells: role for cancer progression.](#)

Dumas JF, Brisson L.

Cancer Metastasis Rev. 2020 Oct 2. **CGO remercié, Projet CONCERTO (AOS CGO/Régions)**

[Cardiolipin, the Mitochondrial Signature Lipid: Implication in Cancer.](#)

Ahmadpour ST, Mahéo K, Servais S, Brisson L, Dumas JF.

Int J Mol Sci. 2020 Oct 28;21(21):8031. **CGO remercié, Projet CONCERTO (AOS CGO/Régions)**

[Development of pyrene-based fluorescent ether lipid as inhibitor of SK3 ion channels.](#)

Bauduin A, Papin M, Chantôme A, Couthon H, Deschamps L, Requejo-Isidro J, Vandier C, Jaffrès PA.

Eur J Med Chem. 2020 Oct 6;209:112894. **CGO remercié**

[Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?](#)

Dolly A, Dumas JF, Servais S.

J Cachexia Sarcopenia Muscle. 2020 Oct 14. **CGO remercié, Projet CONCERTO (AOS CGO/Régions)**

[MEHP/ethanol co-exposure favors the death of steatotic hepatocytes, possibly through CYP4A and ADH involvement.](#)

Tête A, Gallais I, Imran M, Legoff L, Martin-Chouly C, Sparfel L, Bescher M, Sergent O, Podechard N, Lagadic-Gossmann D.

Food Chem Toxicol. 2020 Oct 3;146:111798.



Réseau « Sciences Humaines et Sociales »

[Relationships Between Managerial and Organizational Practices, Psychological Health at Work, and Quality of Care in Pediatric Oncology.](#)

Lejeune J, Chevalier S, Fouquereau E, Chenevert D, Coillot H, Binet A, Gillet N, Mokoukolo R, Michon J, Dupont S, Rachieru P, Gandemer V, Colombat P.

JCO Oncol Pract. 2020 Oct;16(10):e1112-e1119.



« Hub Oncologie 4.0 »

[Comparaison de modèles de prédiction de réadmission non planifiée à 30 jours, à partir des entrepôts de données cliniques et des données démographiques](#)

T.Dhalluin, A.Bannay, P.Lemordant, E.Sylvestre, E.Chazard, M.Cuggia, G.Bouzille

Revue d'Épidémiologie et de Santé Publique, Volume 68, Supplement 3, September 2020, Page S122 ;



Publications inter-réseaux

Réseaux « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »

[Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells](#)

Vinh Nguyen P, Hervé-Aubert K, David S, Lautram N, Passirani C, Chourpa I, Aubrey N, Allard-Vannier E.
Eur J Pharm Biopharm. 2020 Oct 12:S0939-6411(20)30304-0. **CGO remercié, Projet NANOTIF (AOE CGO)**

[Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy \(GETUG-AFU 17\): a randomised, phase 3 trial.](#)

Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P.
Lancet Oncol. 2020 Oct;21(10):1341-1352.

[Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.](#)

Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P.
Cancer Radiother. 2020 Oct 31:S1278-3218(20)30292-4.

[One-year conditional survival of dogs and cats with invasive mammary carcinomas: A concept inspired from human breast cancer.](#)

Chocteau F, Mordelet V, Dagher E, Lousouarn D, Abadie J, Nguyen F.
Vet Comp Oncol. 2020 Sep 21.

[Minimal channel GreenLight photovaporization before permanent implant prostate brachytherapy for patients with obstructive symptoms: Technically feasible and safe.](#)

Peigne C, Fournier G, Dissaux G, Delage F, Coquet JB, Boussion N, Goasduff G, Malhaire JP, Pradier O, Schick U, Valeri A.
Brachytherapy. 2020 Sep 2:S1538-4721(20)30178-1.

Réseaux « Molécules Marines, Métabolisme et Cancer » & « Cancers des Tissus Hormono-dépendants » & « Niches et Epigénétique des Tumeurs »

[Mitochondria at Center of Exchanges between Cancer Cells and Cancer-Associated Fibroblasts during Tumor Progression.](#)

Nocquet L, Juin PP, Souazé F.
Cancers (Basel). 2020 Oct 17;12(10):3017. **CGO remercié, Projet CONCERTO (AOS CGO/Régions).**



Réseaux « Niches et Epigénétique des Tumeurs » & « Cancers des Tissus Hormono-dépendants »

[O-GlcNAcylation Links Nutrition to the Epigenetic Downregulation of UNC5A during Colon Carcinogenesis.](#)
Decourcelle A, Very N, Djouina M, Loison I, Thévenet J, Body-Malapel M, Lelièvre E, Coqueret O, Leprince D, Yazidi-Belkoura IE, Dehennaut V.
Cancers (Basel). 2020 Oct 28;12(11):E3168.



Réseau « Immunothérapies » & « Vectorisation, Imagerie, Radiothérapies »

[Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy.](#)
Mesnard C, Bodet-Milin C, Eugène T, Nguyen JM, Khammari A, Dréno B.
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2261-2267.

